These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1676 related articles for article (PubMed ID: 31160251)

  • 21. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
    Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
    Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
    Tawbi HA; Forsyth PA; Hodi FS; Algazi AP; Hamid O; Lao CD; Moschos SJ; Atkins MB; Lewis K; Postow MA; Thomas RP; Glaspy J; Jang S; Khushalani NI; Pavlick AC; Ernstoff MS; Reardon DA; Kudchadkar R; Tarhini A; Chung C; Ritchings C; Durani P; Askelson M; Puzanov I; Margolin KA
    Lancet Oncol; 2021 Dec; 22(12):1692-1704. PubMed ID: 34774225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
    Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
    Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
    Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
    Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU
    Nat Med; 2021 Feb; 27(2):256-263. PubMed ID: 33558721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
    J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
    Ribas A; Puzanov I; Dummer R; Schadendorf D; Hamid O; Robert C; Hodi FS; Schachter J; Pavlick AC; Lewis KD; Cranmer LD; Blank CU; O'Day SJ; Ascierto PA; Salama AK; Margolin KA; Loquai C; Eigentler TK; Gangadhar TC; Carlino MS; Agarwala SS; Moschos SJ; Sosman JA; Goldinger SM; Shapira-Frommer R; Gonzalez R; Kirkwood JM; Wolchok JD; Eggermont A; Li XN; Zhou W; Zernhelt AM; Lis J; Ebbinghaus S; Kang SP; Daud A
    Lancet Oncol; 2015 Aug; 16(8):908-18. PubMed ID: 26115796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
    Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
    Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
    Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 84.